Literature DB >> 35040875

Medicaid Spending on Drugs Marketed Without US Food and Drug Administration Approval in 2020.

Simon J Gunter1,2, Aaron S Kesselheim1,2, Benjamin N Rome1,2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35040875      PMCID: PMC8767485          DOI: 10.1001/jamainternmed.2021.7614

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  2 in total

1.  Expedited regulatory product approval in the time of COVID-19.

Authors:  Gary D Novack
Journal:  Ocul Surf       Date:  2022-05-28       Impact factor: 6.268

2.  The Vexing Voyage of Vasopressin: The Consequences of Granting Market Exclusivity to Unapproved Drugs.

Authors:  Liam Bendicksen; Aaron S Kesselheim; Benjamin N Rome
Journal:  Chest       Date:  2022-08       Impact factor: 10.262

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.